GSA Capital Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

GSA Capital Partners’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-66,558	Closed	-$235K	–	1607
2020 Q4	$235K	Buy	+66,558	New	+$281K	0.04%	894
2020 Q1	–	Sell	-6,647	Closed	-$86K	–	1688
2019 Q4	$86K	Sell	6,647 -13,696	-67%	-$126K	0.01%	1349
2019 Q3	$214K	Buy	20,343 +6,666	+49%	+$87.1K	0.03%	1142
2019 Q2	$233K	Buy	+13,677	New	+$370K	0.03%	1163

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

GSA Capital Partners's BLCM Position: Q1 2021 in Review

GSA Capital Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2021, closing a stake of 66,558 shares — an estimated $235K sold.

GSA Capital Partners first reported a position in BLCM in Q2 2019 and held it in 4 quarters. The position peaked at $235K in Q4 2020. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2021.

GSA Capital Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
GSA Capital Partners sold 66,558 Bellicum Pharmaceuticals, Inc. shares in Q1 2021, an estimated $235K.
GSA Capital Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2019 and held it in 4 quarters.
GSA Capital Partners's Bellicum Pharmaceuticals, Inc. position peaked at $235K in Q4 2020.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.